How can the EU improve access and affordability of medicines?

As Europe’s population ages, demands on healthcare systems will inevitably increase. Research and development into medicines is expensive, raising questions about costs, equitable access, and affordability. Can technological innovation help drive costs down (and even facilitate more personalised medicine for individual patients)?

How can Europe ensure that the most advanced and effective medicines are not just available to the wealthiest in society, but that they can benefit the public more generally? How can that impulse be balanced against the costs of research and development?

We put some of YOUR questions on this topic to a panel of experts:

•  Nicoletta Luppi, Senior Vice President & Managing Director, MSD Italia
•  Yann Le Cam, Founder & Chief Executive, Eurordis – Rare Disease Europe

How can the EU improve access and affordability of medicines? How is the EU going to make medicine available at quality standards equal to all the citizens of the European Union? What will be the impact of telemedicine and telehealth in general into the future medicine costs? Let us know your thoughts and comments in the form below and we’ll take them to policymakers and experts for their reactions!

Image by aleksandarlittlewolf on Freepik

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.